EUVIMEDEUVIMED entdecken
Crossref

Adverse Effects of Cenobamate in Pediatric Epilepsy: Demographic Considerations

Brooke K Iwamoto, Ashley M Whitaker iD, Latanya D Agurs, Michele M Van Hirtum-Das, Madeline D Kahan iD, Brittany Jordan iD, Leanne Mendoza, Sucheta M Joshi iD, Jenna A Chiang iD

Journal of Child Neurology · 2026-03 · 41 (3) · 336-344

DOI: 10.1177/08830738251357348 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Child Neurology, online erschienen am 29.07.2025. Verfasst von Brooke K Iwamoto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Children's Hospital Los Angeles, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Anticonvulsants, Carbamates, Drug Resistant Epilepsy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study explores trends and potential risk factors among pediatric patients with drug-resistant epilepsy who were prescribed cenobamate by their epileptologist. Twenty-four patients (54.2% female) with drug-resistant (62.5% focal) epilepsy were administered cenobamate (mean = 13.27 years, standard deviation [SD] = 4.91 years) after failing multiple antiseizure medications (mean = 4.83, SD = 2.94). Fifty percent reported improved seizure frequency, although more than half the sample experienced physiological (n = 12, 50%) and/or psychiatric (n = 4, 16.7%) adverse events, with 39% rapidly discontinuing cenobamate (mean = 4.00 months, SD = 3.21) because of intolerable physiological (n = 4, 57.1%) and/or psychiatric adverse events (n = 3, 42.9%). Of those experiencing a psychiatric adverse event, all but 1 (75%) discontinued cenobamate, as compared to discontinuation by only 40% of those experiencing a physiological adverse event (n = 10). Psychiatric adverse events were significantly associated with sex (100% female), χ 2 (1, N = 24) = 4.06, P = .04. Preliminary analyses also suggest older age (adolescence) may increase risk for psychiatric adverse events of cenobamate among patients with pediatric epilepsy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsCarbamatesDrug Resistant EpilepsyHumansMaleFemaleChildAdolescentChild, PreschoolEpilepsyRisk FactorsRetrospective StudiesChlorophenolsTetrazoles

Stichwörter der Autor:innen

antiseizure drugsepilepsypediatricrisk factors

Substanzen

AnticonvulsantsCarbamatesCenobamateChlorophenolsTetrazoles

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Children's Hospital Los Angeles, Los Angeles, CA, USA.
  • Keck School of Medicine of University of Southern California (USC), Los Angeles, CA, USA.
  • Division of Neurology, Children's Hospital Los Angeles, Los Angeles, CA, USA.

ORCID-Profile: Ashley M Whitaker, Madeline D Kahan, Brittany Jordan, Sucheta M Joshi, Jenna A Chiang

Zitieren

APA

Iwamoto, B. K., Whitaker, A. M., Agurs, L. D., Hirtum-Das, M. M. V., Kahan, M. D., Jordan, B., Mendoza, L., Joshi, S. M., & Chiang, J. A. (2026). Adverse Effects of Cenobamate in Pediatric Epilepsy: Demographic Considerations. Journal of Child Neurology, 41(3), 336-344. https://doi.org/10.1177/08830738251357348

Vancouver

Iwamoto BK, Whitaker AM, Agurs LD, Hirtum-Das MMV, Kahan MD, Jordan B, et al. Adverse Effects of Cenobamate in Pediatric Epilepsy: Demographic Considerations. Journal of Child Neurology. 2026;41(3):336-344. doi:10.1177/08830738251357348

BibTeX
@article{Iwamoto2026,
  author = {Iwamoto, Brooke K and Whitaker, Ashley M and Agurs, Latanya D and Hirtum-Das, Michele M Van and Kahan, Madeline D and Jordan, Brittany and Mendoza, Leanne and Joshi, Sucheta M and Chiang, Jenna A},
  title = {Adverse Effects of Cenobamate in Pediatric Epilepsy: Demographic Considerations},
  journal = {Journal of Child Neurology},
  year = {2026},
  volume = {41},
  number = {3},
  pages = {336--344},
  doi = {10.1177/08830738251357348}
}
Kostenlos starten →